CG Oncology, Inc. Common stock (CGON) — Net Asset Quality Index
CG Oncology, Inc. Common stock (CGON) has a Net Asset Quality Index of 95.1% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $791.59 Million minus total liabilities of $38.99 Million yields net assets of $752.60 Million. A higher index indicates a stronger, lower-leverage balance sheet. Read CG Oncology, Inc. Common stock (CGON) financial obligations for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
CG Oncology, Inc. Common stock Net Asset Quality Index Over Time (2021–2025)
This chart shows how CG Oncology, Inc. Common stock's Net Asset Quality Index has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the index stands at 95.1%, representing net assets of $752.60 Million against total assets of $791.59 Million USD. For live market cap and overall valuation, see CGON market cap overview.
Annual Net Asset Quality Index for CG Oncology, Inc. Common stock (2021–2025)
The table below presents the year-by-year Net Asset Quality Index for CG Oncology, Inc. Common stock from 2021 to 2025, covering 5 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. See CGON net asset value for net asset value and shareholders' equity analysis.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 95.1% | $752.60 Million | $791.59 Million | $38.99 Million | ▼ -2.1 pp |
| 2024 | 97.2% | $733.38 Million | $754.80 Million | $21.42 Million | ▲ +4.4 pp |
| 2023 | 92.7% | $184.79 Million | $199.30 Million | $14.51 Million | ▲ +8.0 pp |
| 2022 | 84.7% | $125.18 Million | $147.75 Million | $22.57 Million | ▲ +16.1 pp |
| 2021 | 68.6% | $40.25 Million | $58.69 Million | $18.44 Million | — |